Epizyme’s Tazverik Gets To Market In Rare Sarcoma, Paving Way To Bigger Indications

Accelerated approval in epithelioid sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.

Text Starting Point and yellow pencil on bright background
Now that it has approval in ES, Epizyme will attempt to move Tazverik into larger indications

Epizyme Inc. has its first product approval with the 23 January clearance by the US Food and Drug Administration of Tazverik (tazemetostat) for non-surgical, metastatic or locally advanced epithelioid sarcoma, but that indication largely is meant to clear the way for the first-in-class EZH2 inhibitor to obtain approval for follicular lymphoma and other larger oncology indications.

“We've always viewed this as a way to get into the market and build over time and be prepared for...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip